ReviewFrontiers in immunology2019
Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Immunosuppressive therapy for IgA nephropathy in children.The Cochrane database of systematic reviews · 2024Pooled it
- Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis.Biomolecules & biomedicine · 2023Pooled it
- Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial.BMJ (Clinical research ed.) · 2020Trial
- Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review.BMC nephrology · 2026Article
- Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation.Clinical kidney journal · 2026Article
- Clinical Features and Outcomes of Recurrent IgA Nephropathy After Transplantation: A Case Series and Comparison to Native Disease.Kidney medicine · 2026Article
- Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management.Kidney international reports · 2026Review
- Efficacy and Safety of Telitacicept in Posttransplant Recurrent IgA Nephropathy.Kidney international reports · 2026Article
- Incidence and risk factors for recurrent IgA nephropathy after kidney transplantation: A multicenter cohort study from Denmark.PloS one · 2026Article
- Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review.Journal of clinical medicine · 2025Review
- Bioengineered T-cell therapies for precision immunotherapy in renal transplantation, autoimmune relapse, and sensitization.Clinical kidney journal · 2025Review
- Time-Weighted Average Proteinuria and Renal Function Decline in IgA Nephropathy: A Retrospective Cohort Study.International journal of nephrology and renovascular disease · 2025Article
- Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis.PharmacoEconomics - open · 2025Article
- Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.Clinical kidney journal · 2024Review
- Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.BMC nephrology · 2024Review
- Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential.CPT: pharmacometrics & systems pharmacology · 2024Article
- Sinomenine Hydrochloride Protects IgA Nephropathy Through Regulating Cell Growth and Apoptosis of T and B Lymphocytes.Drug design, development and therapy · 2024Article
- A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. The disease generally runs an indolent course but may lead to ESRD in 20-30% of patients in 20 years or more after diagnosis. Patients with IgA nephropathy are ideal candidates for renal transplant because they are generally relatively young and with few comorbidities. Their graft survival is better or comparable to that of controls at 10 years, though few data are available after 10 years of follow-up. Recurrence of the original disease in the graft is a well-known complication of transplant in IgAN and is a significant cause of deterioration of graft function. Recurrent IgAN rarely manifests clinically before 3 years post transplantation. Recurrence rate is estimated to be around 30% with considerable differences among different series. Despite these factors there is no certain recurrence predictor, young age at renal transplant, rapid progression of the original disease and higher levels of circulating galactose-deficient IgA1 and IgA-IgG immune complexes are all associated with a higher rate of recurrence. Which pathogenetic mechanisms are responsible for the progression of the recurrence to graft function deterioration, and what therapy can prevent or slow down the progression of the disease in the graft, are open questions. The aim of this review is to describe the clinical outcome of renal transplantation in IgA patients with attention to the rate and the predictors of recurrence and to discuss the available therapeutic options for the management of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.